Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Pneumococcal Δpep27 Immunization Attenuates TLRs and NLRP3 Expression and Relieves Murine Ovalbumin-Induced Allergic Rhinitis

  • Yu, Jae Ik (School of Pharmacy, Sungkyunkwan University) ;
  • Kim, Ji-Hoon (School of Pharmacy, Sungkyunkwan University) ;
  • Nam, Ki-El (School of Pharmacy, Sungkyunkwan University) ;
  • Lee, Wonsik (School of Pharmacy, Sungkyunkwan University) ;
  • Rhee, Dong-Kwon (School of Pharmacy, Sungkyunkwan University)
  • Received : 2022.03.03
  • Accepted : 2022.04.15
  • Published : 2022.06.28
Download PDF
⟨ Previous Next ⟩

Abstract

Allergic rhinitis (AR), one of the most common inflammatory diseases, is caused by immunoglobulin E (IgE)-mediated reactions against inhaled allergens. AR involves mucosal inflammation driven by type 2 helper T (Th2) cells. Previously, it was shown that the Streptococcus pneumoniae pep27 mutant (Δpep27) could prevent and treat allergic asthma by reducing Th2 responses. However, the underlying mechanism of Δpep27 immunization in AR remains undetermined. Here, we investigated the role of Δpep27 immunization in the development and progression of AR and elucidated potential mechanisms. In an ovalbumin (OVA)-induced AR mice model, Δpep27 alleviated allergic symptoms (frequency of sneezing and rubbing) and reduced TLR2 and TLR4 expression, Th2 cytokines, and eosinophil infiltration in the nasal mucosa. Mechanistically, Δpep27 reduced the activation of the NLRP3 inflammasome in the nasal mucosa by down-regulating the Toll-like receptor signaling pathway. In conclusion, Δpep27 seems to alleviate TLR signaling and NLRP3 inflammasome activation to subsequently prevent AR.

Keywords

Acknowledgement

This work was supported by the National Research Foundation grant (NRF-2018R1A2A1A05078102) and the Technology development Program of MSS (S3201794). The funding body played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  1. Small P, Keith PK, Kim H. 2018. Allergic rhinitis. Allergy Asthma Clin. Immunol. 14: 51. https://doi.org/10.1186/s13223-018-0280-7
  2. Stuck BA, Czajkowski J, Hagner AE, Klimek L, Verse T, Hormann K, et al. 2004. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J. Allergy Clin. Immunol. 113: 663-668. https://doi.org/10.1016/j.jaci.2003.12.589
  3. Bauchau V, Durham SR. 2005. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 60: 350-353. https://doi.org/10.1111/j.1398-9995.2005.00751.x
  4. Ha J, Lee SW, Yon DK. 2020. Ten-year trends and prevalence of asthma, allergic rhinitis, and atopic dermatitis among the Korean population, 2008-2017. Clin. Exp. Pediatr. 63:278-283. https://doi.org/10.3345/cep.2019.01291
  5. van de Veen W, Akdis M. 2019. The use of biologics for immune modulation in allergic disease. J. Clin. Invest. 129: 1452-1462. https://doi.org/10.1172/jci124607
  6. Dykewicz MS, Hamilos DL. 2010. Rhinitis and sinusitis. J. Allergy Clin. Immunol. 125: S103-115. https://doi.org/10.1016/j.jaci.2009.12.989
  7. Thorburn AN, Tseng HY, Donovan C, Hansbro NG, Jarnicki AG, Foster PS, et al. 2016. TLR2, TLR4 and MyD88 mediate allergic airway disease (AAD) and Streptococcus pneumoniae-induced suppression of AAD. PLoS One 11: e0156402. https://doi.org/10.1371/journal.pone.0156402
  8. Ryu JH, Yoo JY, Kim MJ, Hwang SG, Ahn KC, Ryu JC, et al. 2013. Distinct TLR-mediated pathways regulate house dust mite-induced allergic disease in the upper and lower airways. J. Allergy Clin. Immunol. 131: 549-561. https://doi.org/10.1016/j.jaci.2012.07.050
  9. Kim BG, Ghosh P, Ahn S, Rhee DK. 2019. Pneumococcal pep27 mutant immunization suppresses allergic asthma in mice. Biochem. Biophys. Res. Commun. 514: 210-216. https://doi.org/10.1016/j.bbrc.2019.04.116
  10. Lee S, Ghosh P, Kwon H, Park SS, Kim GL, Choi SY, et al. 2018. Induction of the pneumococcal vncRS operon by lactoferrin is essential for pneumonia. Virulence 9: 1562-1575. https://doi.org/10.1080/21505594.2018.1526529
  11. Kim EH, Choi SY, Kwon MK, Tran TD, Park SS, Lee KJ, et al. 2012. Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice. Vaccine 30: 2008-2019. https://doi.org/10.1016/j.vaccine.2011.11.073
  12. Kim SH, Jang YS. 2017. The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants. Clin. Exp. Vaccine Res. 6: 15-21. https://doi.org/10.7774/cevr.2017.6.1.15
  13. Giudice EL, Campbell JD. 2006. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 58: 68-89. https://doi.org/10.1016/j.addr.2005.12.003
  14. Kersten G, Hirschberg H. 2007. Needle-free vaccine delivery. Expert. Opin. Drug Deliv. 4: 459-474. https://doi.org/10.1517/17425247.4.5.459
  15. Seon SH, Choi JA, Yang E, Pyo S, Song MK, Rhee DK. 2018. Intranasal immunization with an attenuated pep27 mutant provides protection from influenza virus and secondary pneumococcal infections. J. Infect. Dis. 217: 637-640. https://doi.org/10.1093/infdis/jix594
  16. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. et al. 2001. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 108: S147-334. https://doi.org/10.1067/mai.2001.118891
  17. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, et al. 1992. Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J. Immunol. 148: 2390-2394. https://doi.org/10.4049/jimmunol.148.8.2390
  18. Fransson M, Adner M, Erjefalt J, Jansson L, Uddman R, Cardell LO. 2005. Up-regulation of Toll-like receptors 2, 3 and 4 in allergic rhinitis. Respir. Res. 6: 100. https://doi.org/10.1186/1465-9921-6-100
  19. Zhong Q, Zhan M, Wang L, Chen D, Zhao N, Wang J, et al. 2021. Upregulation of the expression of Toll-like receptor 9 in basophils in patients with allergic rhinitis: An enhanced expression by allergens. Scand. J. Immunol. 93: e13003.
  20. Kirtland ME, Tsitoura DC, Durham SR, Shamji MH. 2020. Toll-like receptor agonists as adjuvants for allergen immunotherapy. Front. Immunol. 11:599083. https://doi.org/10.3389/fimmu.2020.599083
  21. Yang Z, Liang C, Wang T, Zou Q, Zhou M, Cheng Y, et al. 2020. NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis. Biochem. Biophys. Res. Commun. 522: 61-67. https://doi.org/10.1016/j.bbrc.2019.11.031
  22. Zhang W, Ba G, Tang R, Li M, Lin H. 2020. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model. Int. Immunopharmacol. 83: 106394. https://doi.org/10.1016/j.intimp.2020.106394
  23. Annunziato F, Romagnani C, Romagnani S. 2015. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 135: 626-635. https://doi.org/10.1016/j.jaci.2014.11.001
  24. Gour N, Wills-Karp M. 2015. IL-4 and IL-13 signaling in allergic airway disease. Cytokine 75: 68-78. https://doi.org/10.1016/j.cyto.2015.05.014
  25. Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW. 2001. Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir. Res. 2: 71-79. https://doi.org/10.1186/rr41
  26. Aryan Z, Holgate ST, Radzioch D, Rezaei N. 2014. A new era of targeting the ancient gatekeepers of the immune system: Toll-like agonists in the treatment of allergic rhinitis and asthma. Int. Arch. Allergy Immunol. 164: 46-63. https://doi.org/10.1159/000362553
  27. Xu H, Shu H, Zhu J, Song J. 2019. Inhibition of TLR4 inhibits allergic responses in murine allergic rhinitis by regulating the NF-κB pathway. Exp. Ther. Med. 18: 761-768.
  28. Zhao CC, Xie QM, Xu J, Yan XB, Fan XY, Wu HM. 2020. TLR9 mediates the activation of NLRP3 inflammasome and oxidative stress in murine allergic airway inflammation. Mol. Immunol. 125: 24-31. https://doi.org/10.1016/j.molimm.2020.06.016
  29. Velasco G, Campo M, Manrique OJ, Bellou A, He HZ, Arestides RSS, et al. 2005. Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am. J. Resp. Cell Mol. 32: 218-224. https://doi.org/10.1165/rcmb.2003-0435OC
  30. Starkhammar M, Larsson O, Georen SK, Leino M, Dahlen SE, Adner M, et al. 2014. Toll-like receptor ligands LPS and poly (I:C) exacerbate airway hyperresponsiveness in a model of airway allergy in mice, independently of inflammation. PLoS One 9:e104114. https://doi.org/10.1371/journal.pone.0104114
  31. Gupta GK, Agrawal DK. 2010. CpG oligodeoxynucleotides as TLR9 agonists therapeutic application in allergy and asthma. BioDrugs 24: 225-235. https://doi.org/10.2165/11536140-000000000-00000
  32. Aryan Z, Rezaei N. 2015. Toll-like receptors as targets for allergen immunotherapy. Curr. Opin. Allergy Clin. Immunol. 15: 568-574. https://doi.org/10.1097/ACI.0000000000000212
  33. Hayashi T, Raz E. 2006. TLR9-based immunotherapy for allergic disease. Am. J. Med. 119: 897.e1-6. https://doi.org/10.1016/j.amjmed.2005.12.028
  34. Horak F. 2011. VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin. Inv. Drug. 20: 981-986. https://doi.org/10.1517/13543784.2011.583237
  35. Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, Zahringer U, et al. 2003. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 278: 15587-15594. https://doi.org/10.1074/jbc.M212829200
  36. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. 1999. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163: 1-5. https://doi.org/10.4049/jimmunol.163.1.1
  37. Goodridge HS, McGuiness S, Houston KM, Egan CA, Al-Riyami L, Alcocer MJ, et al. 2007. Phosphorylcholine mimics the effects of ES-62 on macrophages and dendritic cells. Parasite Immunol. 29: 127-137. https://doi.org/10.1111/j.1365-3024.2006.00926.x
  38. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, et al. 2003. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. USA 100: 1966-1971. https://doi.org/10.1073/pnas.0435928100
  39. Kim BY, Shin JH, Park HR, Kim SW, Kim SW. 2013. Comparison of antiallergic effects of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine in a murine model of allergic rhinitis. Laryngoscope 123: 2371-2377. https://doi.org/10.1002/lary.24047
  40. Sutterwala FS, Haasken S, Cassel SL. 2014. Mechanism of NLRP3 inflammasome activation. Ann. NY Acad. Sci. 1319: 82-95. https://doi.org/10.1111/nyas.12458
  41. Swanson KV, Deng M, Ting JP. 2019. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19: 477-489. https://doi.org/10.1038/s41577-019-0165-0
  42. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. 2009. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183: 787-791. https://doi.org/10.4049/jimmunol.0901363
  43. Boucher D, Monteleone M, Coll RC, Chen KW, Ross CM, Teo JL, et al. 2018. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J. Exp. Med. 215: 827-840. https://doi.org/10.1084/jem.20172222
  44. Paul WE, Zhu J. 2010. How are T(H)2-type immune responses initiated and amplified? Nat. Rev. Immunol. 10: 225-235. https://doi.org/10.1038/nri2735
  45. Caucheteux SM, Hu-Li J, Guo L, Bhattacharyya N, Crank M, Collins MT, et al. 2016. IL-1β enhances inflammatory TH2 differentiation. J. Allergy Clin. Immunol. 138: 898-901.e4. https://doi.org/10.1016/j.jaci.2016.02.033
  46. Chen CY, Kao CL, Liu CM. 2018. The cancer prevention, anti-inflammatory and anti-oxidation of bioactive phytochemicals targeting the TLR4 signaling pathway. Int. J. Mol. Sci. 19: 2729. https://doi.org/10.3390/ijms19092729